Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
CAPRICOR THERAPEUTICS, INC. (CAPR)
A forensic read on CAPRICOR THERAPEUTICS, INC. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
6.9
Altman Z-score
Clean
Earnings quality
3
Forensic signals
-59.3%
ROE
$1.5B
Market cap
CAPRICOR THERAPEUTICS, INC. earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is 6.9, placing it in the Safe zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-265%Return on invested capital.Return on invested capital is -265% and slipping from -139% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+29.8%/yrShare-count dilution.Diluted share count changed +89% over the last 3 years to FY2025 (+29.8%/yr). The count is GROWING — existing holders are being diluted. That's ~29.8% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~89%.
stoppedShareholder returns — halted.Capital returns have STOPPED — $193 of buybacks + dividends in FY2019, but ~$0 in FY2020. A halt usually means the company is conserving cash; understand why before reading it as neutral.
Key fundamentals
Free Cash Flow$-72.7M
Return on Equity-34.4%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on CAPRICOR THERAPEUTICS, INC.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about CAPR's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown